BRCA1 and primary biliary cholangitis: Within the subset of 26 patients recommended PBC/olaparib therapy, 12 were prescribed olaparib as a PARP inhibitor based solely on their positive GIS status, whereas the remaining 14 also harbored additional BRCA1/2 pathogenic variants.